Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Brain Cancer Clinical Trials

A listing of Brain Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (55) clinical trials

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

This is a phase I/II study of mebendazole in combination with standard of care agents for pediatric patients with gliomas. Patients with low-grade gliomas will receive a regimen of mebendazole in combination with vincristine, carboplatin, and temozolomide. Patients with high-grade gliomas and diffuse intrinsic pontine gliomas will receive a regimen ...


Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors

PROTOCOL SUMMARY: Phase 1: Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and toxicity profile. Phase 2: Patients with recurrent or progressive tumors signaling through the ras/raf pathway after standard up-front therapy ...


Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

The experimental aspects of this treatment plan will include: Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 25%; 10 mL over 2 minutes) in order to disrupt the blood brain barrier. This technique has been used in several thousand patients in previous studies for the IA ...


A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70

In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2 for 6 cycles or until the disease progresses.


Cambridge Brain Mets Trial 1

Brain metastases occur in 20-40% of all patients with cancer, with an incidence 10 times higher than that of primary malignant brain tumours. patients with brain metastases are an underserved population. Overall they have a poor prognosis with a median survival of 1-2 months with corticosteroids and only 5-7 months ...


Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy TG6002/5-FC in Recurrent Glioblastoma Patients

Phase 1: This is a Phase 1, open-label, dose-escalation trial using an accelerated titration 3+3 design in patients with recurrent glioblastoma. Eligible patients will first be consecutively enrolled in a one-patient cohort at lowest dose level and then in 3-patients cohorts up to a DLT observation. In case a DLT ...


Synchrotron Radiation to the Treatment of Intracranial Tumors

Synchrotron radiation (SR) is used to produce monochromatic X-ray photons of very high intensity with tunable energy in the range of medium energies (0-150 keV). Thus freed of low energies, the penetration is still important and the types of possible interactions are, in addition to the Compton Effect in water, ...


CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.


Tumor Resection and Gliadel Wafers Followed by Temodar With Standard Radiation or GammaKnife for New GBM

The primary purpose of this study is to determine if single fraction GK radiosurgical treatment to the resection bed can achieve equivalent local control and survival for patients with GBM after GTR, Gliadel implant and temozolomide therapy compared to patients receiving standard postoperative RT with temozolomide, but offer improved quality ...


Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours

This is a phase I, dose escalation study where topotecan will be administered at lower doses given more frequently on a prolonged schedule (low dose metronomic; LDM), in combination with a fixed dose of pazopanib. The maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) will be evaluated ...